

Bibliography: Study Design and Risk-Benefit Analysis

- Ackerman, T. F. (1992). Balancing moral principles in federal regulations on human research. *IRB: A Review of Human Subjects Research*, 14(1), 1-6.
- Ackerman, T. F. (1996). Choosing between Nuremberg and the National Commission: The balancing of moral principles in clinical research. In H.Y. Vanderpool (Ed.), *The ethics of research involving human subjects: Facing the 21st century* (pp. 83-104). Frederick, MD: University Publishing Group, Inc.
- Ackerman, T. F. (2002). Therapeutic beneficence and placebo controls. *The American Journal of Bioethics*, 2(2), 21-22.
- Amdur, R. J. & Biddle, C. J. (2002). The placebo-controlled clinical trial. *Institutional review board: Management and function*. Sudbury MA: Jones and Bartlett, 450-457.
- Appelbaum, P. S. (1996). Drug-free research in schizophrenia: An overview of the controversy. *IRB: A Review of Human Subjects Research*, 18(1), 1-5.
- Barnbaum, D. (2002). Making more sense of 'minimal risk'. *IRB: Ethics & Human Research*, 24(3), 10-13.
- Bergsma, J. (1997). Response to 'Ethical concerns about relapse studies' by Adil E. Shamoo and Timothy J. Keay (CQ Vol 5, No 3). *Cambridge Quarterly of Healthcare Ethics*, 6, 233-234.
- Borowsky, S. J., Rubenstein, L. V., et al. (2000). Who is at risk of nondetection of mental health problems in primary care? *Journal of General Internal Medicine* 15(6), 381-388.
- Box, J. E. (2004). Placebos and the UK Medical Research Council- and the consumer perspective. *Science and Engineering Ethics* 10(1), 95-101.
- Breggin, P. R. (2000). A critical analysis of NIMH multimodal treatment study for attention-deficit/hyperactivity disorder (The MTA Study). *Ethical Human Sciences and Services*, 2(1), 63-72.
- Carpenter, W. T., Schooler, N. R., et al. (1997). The rationale and ethics of medication-free research in schizophrenia. *Archives of General Psychiatry*, 54, 401-407.
- Carpenter Jr., W. T. (1999). The schizophrenia ketamine challenge study debate. *Biological Psychiatry*, 46(8), 1081-1091.
- Cassell, E. J. (2000). The principles of the Belmont Report revisited: How have respect for persons, beneficence, and justice been applied to clinical medicine? *Hastings Center Report*, 30(4), 12-21.

- Cohen, P. J. (2002). Failure to conduct a placebo-controlled trial may be unethical. *The American Journal of Bioethics*, 2(2), 24.
- Crouch, R. A. (2001). Eligibility, extrapolation, and equipoise: Unlearned lessons in the ethical analysis of clinical research. *IRB: Ethics & Human Research*, 23(4), 6-9.
- D'Souza, D. C., Berman, R. M., et al. (1999). Symptom provocation studies in psychiatric disorders: Scientific value, risks and future. *Biological Psychiatry*, 46(8), 1060-1080.
- Evans, M., Robling, M. et al. (2002). It doesn't cost anything to ask, does it? The ethics of questionnaire-based research. *Journal of Medical Ethics*, 28(1), 41-44.
- Ferrell, R. B. (2002). Treatment-withholding studies in psychiatry. In R. J. Amdur and E. A. Bankert (Eds.), *Institutional review board: Management and function* (pp. 461-464). Sudbury, MA: Jones and Bartlett.
- Fins, J. J. (1997). The call of the sirens: Navigating the ethics of medication-free research in schizophrenia. *Archives of General Psychiatry*, 54, 415-416.
- Fisher, C. B. & Rosendahl, S. A. (1990). Psychological Risks and Remedies of Research Participation. In C. B. Fisher and W. W. Tryon (Eds.), *Ethics in applied developmental psychology: Emerging issues in an emerging field* (pp. 4, 43-59). Norwood, NJ: Ablex Publishing Corporation.
- Fisher, C. B. & Wallace, S. A. (2000). Through the community looking glass: Reevaluating the ethical and policy implications of research on adolescent risk and psychopathology. *Ethics & Behavior*, 10(2), 99-118.
- Food and Drug Administration (1999). *Choice of control group in clinical trials*. Rockville, MD: Food and Drug Administration.
- Freedman, B. (1987). Equipoise and the ethics of clinical research. *New England Journal of Medicine*, 317(3), 141-145.
- Freedman, B. (1990). Placebo-controlled trials and the logic of clinical purpose. *IRB: A Review of Human Subjects Research*, 12(6), 1-6.
- Freedman, B. (1996). The ethical analysis of clinical trials: New lessons for and from cancer research. In H.Y. Vanderpool (Ed.), *The ethics of research involving human subjects: Facing the 21st century* (pp. 319-338). Frederick, MD: University Publishing Group, Inc.
- Getz, K. & Borfritz, D. (2002). *Informed consent: A guide to the risks and benefits of volunteering for clinical trials*. Boston: CenterWatch.
- Glass, K. C. & Waring, D. (2002). Effective trial design need not conflict with good patient care. *The American Journal of Bioethics*, 2(2), 25-26.
- Gordon, V. M., Sugarman, J., et al. (1998). Toward a more comprehensive approach to protecting human subjects: The interface of data safety monitoring boards and institutional review boards in randomized clinical trials. *IRB: A Review of Human Subjects Research*, 20(1), 1-5.
- Hadjistavropoulos, T. & Smythe, W. E. (2001). Elements of risk in qualitative research. *Ethics & Behavior*, 11(2), 163-174.

- Hall, L. L. (1999). Medication discontinuation and symptom provocation in research: A consumer and family perspective. *Biological Psychiatry*, 46(8), 1017-1020.
- Haverkamp, B. E. (2005). Ethical perspectives on qualitative research in applied psychology. *Journal of Counseling Psychology*, 52(2), 146-155.
- Healy, D. (2002). *Randomized Controlled Trials: Evidence Based Psychiatry*. Alliance for Human Research Protection. Available from: <http://www.ahrp.org/COI/healy0802.html>.
- Healy, D. (2002). Are Concerns about the Ethics of Placebos a Stalking Horse for Other Issues? *The American Journal of Bioethics*, 2(2), 17-19.
- Helmchen, H. & Muller-Oerlinghausen, B. (1975). The inherent paradox of clinical trials in psychiatry. *Journal of Medical Ethics*, 1, 168-173.
- Henn, F. A., Lader, M., et al. (1997). Medication-free research with schizophrenic patients: A european perspective. *Archives of General Psychiatry*, 54(5), 412-413.
- Horvath, P. (1988). Placebos and common factors in two decades of psychotherapy research. *Psychological Bulletin*, 104(2), 214-225.
- Hyman, S. E. & Shore, D. (2000). An NIMH perspective on the use of placebos. *Biological Psychiatry*, 47, 689-691.
- Irving, D. N. & Shamoo, A. E. (1997). Washout/relapses in patients participating in neurobiological research studies in schizophrenia. In A. E. Shamoo (Ed.), *Ethics in neurobiological research with human subjects: The Baltimore Conference on Ethics* (pp. 119-127). Amsterdam: Gordon and Breach Publishers.
- Jecker, N. S. (2002). Exploiting subjects in placebo-controlled trials. *The American Journal of Bioethics*, 2(2), 19-20.
- Jonsen, A. R. (1989). The ethics of using human volunteers for high-risk research. *Journal of Infectious Diseases*, 160(2), 205-208.
- Kane, J. & Borenstein, M. (1997). The use of placebo controls in psychiatric research. In A. E. Shamoo (Ed.), *Ethics in neurobiological research with human subjects: The Baltimore Conference on Ethics* (pp. 207-214). Amsterdam: Gordon and Breach Publishers.
- Khan, A., Warner, H. A., et al. (2000). Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: An analysis of the Food and Drug Administration database. *Archives of General Psychiatry*, 57, 311-317.
- Kienle, G. S. & Kiene, H. (1997). The Powerful Placebo Effect: Fact or Fiction. *Journal of Clinical Epidemiology*, 50(12), 1311-1318.
- Kim, S. Y. H. (2003). Benefits and burdens of placebos in psychiatric research. *Psychopharmacology*, 171(1), 13-18.
- Klerman, G. L. (1986). Scientific and ethical considerations in the use of placebo controls in clinical trials in psychopharmacology. *Psychopharmacology Bulletin*, 22(1), 25-29.

- Koocher, G. P. (2002). Using the CABLES model to assess and minimize risk in research: Control group hazards. *Ethics & Behavior, 12*, 75-86.
- Kopelman, L. M. (2000). Moral problems in assessing research risk. *IRB: A Review of Human Subjects Research, 22*(5), 3-6.
- Kraemer, H. C. (2000). Statistical analysis to settle ethical issues? *Archives of General Psychiatry, 57*, 327-328.
- Leber, P. (2000). Placebo controls: No news is good news. *Archives of General Psychiatry, 57*, 319-320.
- Levine, R. J. (1998). The 'Best proven therapeutic method' standard in clinical trials in technologically developing countries. *IRB: A Review of Human Subjects Research, 20*(1), 5-9.
- Margolin, G., Chien, D., Duman, S. E., Fauchier, A., Gordis, E. B., Oliver, P. H., et al. (2005). Ethical issues in couple and family research. *Journal of Family Psychology, 19*(1), 157-167.
- Martin, D. K., Meslin, E. M., et al. (1995). The incommensurability of research risks and benefits: Practical help for research ethics committees. *IRB: A Review of Human Subjects Research, 17*(2), 8-10.
- Mastroianni, A. C. & Kahn, J. (2001). Swinging on the pendulum: Shifting views of justice in human subjects research. *Hastings Center Report, 31*(3), 21-28.
- Michels, K. B. (2000). The placebo problem remains. *Archives of General Psychiatry, 57*, 321-322.
- Michels, K. B. & Rothman, K. J. (2003). Update on unethical use of placebos in randomized trials. *Bioethics, 17*(2), 188-204.
- Miller, F. G. (2000). Placebo-controlled trials in psychiatric research: An ethical perspective. *Biological Psychiatry, 47*, 707-716.
- Miller, F. G. & Brody, H. (2002). What makes placebo-controlled trials unethical? *The American Journal of Bioethics, 2*(2), 3-9.
- Miller, P. B. & Weijer, C. (2003). Rehabilitating equipoise. *Kennedy Institute of Ethics Journal, 13*(2), 93-118.
- Moreno, J. D. (2000). *Undue risk. Secret state experiments on humans*. New York: W.H. Freeman and Company.
- Olson-Garewal, J. K. & Hessler, K. (2001). Arizona's cancer clinical trials law: flawed process, flawed product. *Hastings Center Report, 31*(3), 22-24.
- Oquendo, M., Stanley, B., Ellis, S., & Mann, J. (2004). Protection of human subjects in intervention research for suicidal behavior. *American Journal of Psychiatry, 161*(9), 1558-1563.
- Puzynski, S. (2004). Placebo in the investigation of psychotropic drugs, especially antidepressants. *Science and Engineering Ethics, 10*(1), 135-142.
- Quitkin, F. M. & Klein, D. F. (2000). What conditions are necessary to assess antidepressant efficacy? *Archives of General Psychiatry, 57*, 323-324.

- Rose, L. E. (1986). Ethical considerations of patient involvement in clinical psychiatric research. *Canada's Mental Health, 34*(2), 8-11.
- Rosenstein, D. L. (1999). IRB Review of Psychiatric Medication Discontinuation and Symptom-Provoking Studies. *Biological Psychiatry, 46*, 1039-1043.
- Rothman, K. J. & Michels, K. B. (1994). The continuing unethical use of placebo controls. *The New England Journal of Medicine, 331*(6), 394-398.
- Saks, E. R., Jeste, D. V., et al. (2002). Ethical issues in psychosocial interventions research involving controls. *Ethics & Behavior, 12*(1), 87-101.
- Scott, C. K., & White, W. L. (2005). Ethical issues in the conduct of longitudinal studies of addiction treatment. *Journal of Substance Abuse Treatment, 28*(Suppl 1), S91-S101.
- Sharav, V. H. (1999). The ethics of conducting psychosis-inducing experiments. *Accountability in Research, 7*, 137-167.
- Stanley, B. (1988). An integration of ethical and clinical considerations in the use of placebos. *Psychopharmacology Bulletin, 24*(1), 18-20.
- Street, L. L. & Luoma, J. B. (2002). Control groups in psychosocial intervention research: Ethical and methodological issues. *Ethics & Behavior, 12*(1), 1-29.
- Sugarman, J. (2004). Using empirical data to inform the ethical evaluation of placebo controlled trials. *Science and Engineering Ethics, 10*(1), 29-35.
- Veatch, R. M. (2002). Subject indifference and the justification of placebo-controlled trials. *The American Journal of Bioethics, 2*(2), 12-13.
- Wyatt, R. J., Henter, I. D., et al. (1999). The long-term effects of placebo in patients with chronic schizophrenia. *Biological Psychiatry, 46*(8), 1092-1105.